Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------|-------|-----------|-------|-----------|-------|-----------|-------|-----------|-----------|----------|-----------|-------|-----------|-------|----------| | | | 1Q | | 2Q | June | YTD | | 2Q | June YTD | 3Q | 4Q | Full | Year | 2Q ...

The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024.Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug. The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion on increased demand f ...

GERMANY - 2024/02/20: In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesMerck (NYSE: MRK) will report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $15.9 billion and adjusted earnings of $2.20, slightly ahead of the street estimates. As usual, Keytruda will be driving the growth for Merck with quarterly sales estim ...

Wall Street analysts expect Merck (MRK) to post quarterly earnings of $2.16 per share in its upcoming report, which indicates a year-over-year increase of 204.9%. Revenues are expected to be $15.9 billion, up 5.7% from the year-ago quarter.The current level reflects a downward revision of 6.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's ...

We Are Investment Overview Merck & Co. (NYSE:MRK), the New Jersey based pharmaceutical giant, will announce its Q2 2024 earnings next Tuesday, 30th July. Yesterday, the company declared a $0.77 per share quarterly dividend, representing an annual yield of 2.48%. After reaching highs of ~$90 per share in 2000 / 2001, Merck's share price took another 20 years before hitting such heights again, but the past three years have seen shareholders rewarded with exceptional gains. On a 3-year basis, shares have r ...

Merck (MRK) will report its second-quarter earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.85 billion and $2.15 per share, respectively. Earnings estimates for Merck have risen from $8.58 to $8.60 per share over the past seven days. For 2025, earnings estimates have risen from $9.94 to $9.96 per share over the same timeframe.Image Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been solid, with ...

The market expects Merck (MRK) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 30, 2024, might help the stock move higher if these key numbers are better tha ...

The most recent trading session ended with Merck (MRK) standing at $125.69, reflecting a -0.06% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 1.08%. On the other hand, the Dow registered a gain of 0.32%, and the technology-centric Nasdaq increased by 1.58%.The the stock of pharmaceutical company has fallen by 3.79% in the past month, lagging the Medical sector's gain of 0.31% and the S&P 500's gain of 0.43%.Market participants will be closely following the fi ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this pharmaceutical company have returned -1.6%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Merck falls in, has gained 2.2%. The key question now is: What could be the stock's future directio ...

Merck’s (MRK) stock has risen 17.5% so far this year, underperforming an increase of 24.2% for the industry, as seen in the chart below. Merck Stock Underperforms Industry Image Source: Zacks Investment ResearchMerck boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda approved for several types of cancer and alone accounting for more than 45% of the company’s pharmaceutical sales. The drug has played an instrumental role in driving Merck’s steady revenue growth in the past ...